SCM
ACER

Stonepine Capital Management’s Acer Therapeutics Inc ACER Stock Holding History

Stonepine Capital Management’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,000
Closed -$80K – 31
2019
Q4 		$80K Sell
20,000
-94,175
-82% -$320K 0.06% 23
2019
Q3 		$364K Buy
+114,175
New +$335K 0.35% 22
2018
Q1 		– Sell
-100,000
Closed -$1.39M – 38
2017
Q4 		$1.39M Buy
+100,000
New +$1.63M 0.83% 22

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stonepine Capital Management's ACER Position: Q1 2020 in Review

Stonepine Capital Management sold out of Acer Therapeutics Inc (ACER) in Q1 2020, closing a stake of 20,000 shares — an estimated $80K sold.

Stonepine Capital Management first reported a position in ACER in Q4 2017 and held it in 3 quarters. The position peaked at $1.39M in Q4 2017. 37 funds tracked by Wall St. Rank hold ACER as of Q1 2020.

  • Stonepine Capital Management reported no remaining Acer Therapeutics Inc position as of Q1 2020 after selling out during the quarter.
  • Stonepine Capital Management sold 20,000 Acer Therapeutics Inc shares in Q1 2020, an estimated $80K.
  • Stonepine Capital Management first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 3 quarters.
  • Stonepine Capital Management's Acer Therapeutics Inc position peaked at $1.39M in Q4 2017.
  • 37 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2020.

Based on Stonepine Capital Management's 13F filing for Q1 2020, filed 14 May 2020.